Literature DB >> 25613637

Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin.

Eugenia Yiannakopoulou1.   

Abstract

Although botulinum toxin is generally considered safe, its widespread use and the constantly expanded indications raise safety issues. This study aimed to review the serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Serious adverse events included dysphagia, respiratory compromise, generalized muscle weakness, marked bilateral ptosis, pseudoaneurysm of the frontal branch of the temporal artery, necrotizing fasciitis, sarcoidal granuloma, Fournier gangrene, and cervical kyphosis. Death was attributed to botulism or anaphylactic shock. In conclusion, botulinum toxin may cause serious adverse events, which are more common after its therapeutic use, but can also be noticed after its cosmetic use. Thorough knowledge of the anatomy of the treated muscles and of the pharmacology of the drug is imperative to avoid serious adverse events.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25613637     DOI: 10.1159/000370245

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  30 in total

1.  Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database.

Authors:  Salma Ahsanuddin; Savannah Roy; Wissam Nasser; Roman Povolotskiy; Boris Paskhover
Journal:  Aesthetic Plast Surg       Date:  2020-10-30       Impact factor: 2.326

Review 2.  A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications.

Authors:  Nitin Sethi; Sukhbir Singh; Koenraad DeBoulle; Eqram Rahman
Journal:  Aesthetic Plast Surg       Date:  2020-10-13       Impact factor: 2.326

3.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

Review 4.  Heart-Shaped Bilateral Medullary Pyramidal Infarction as a Pathognomonic Finding of Anterior Spinal Artery Occlusion.

Authors:  Sammy Searcy; Oluwaseun O Akinduro; Andrew Spector; Jang W Yoon; Benjamin L Brown; William D Freeman
Journal:  Neurocrit Care       Date:  2018-06       Impact factor: 3.210

Review 5.  Image-guided botulinum toxin injection in the lateral abdominal wall prior to abdominal wall reconstruction surgery: review of techniques and results.

Authors:  Eva B Deerenberg; Sharbel A Elhage; Robert J Raible; Jenny M Shao; Vedra A Augenstein; B Todd Heniford; Robert Lopez
Journal:  Skeletal Radiol       Date:  2020-07-04       Impact factor: 2.199

6.  Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease.

Authors:  Lewis D Turner; Alexander L Nielsen; Lucy Lin; Antonio J Campedelli; Nicholas R Silvaggi; Jason S Chen; Amanda E Wakefield; Karen N Allen; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2021-07-28       Impact factor: 4.632

7.  Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A.

Authors:  Lucy Lin; Lewis D Turner; Peter Šilhár; Sabine Pellett; Eric A Johnson; Kim D Janda
Journal:  RSC Med Chem       Date:  2020-11-12

8.  Use of AbobotulinumtoxinA for Cosmetic Treatments in the Neck, and Middle and Lower Areas of the Face: A Systematic Review.

Authors:  Hassan Galadari; Ibrahim Galadari; Riekie Smit; Inna Prygova; Alessio Redaelli
Journal:  Toxins (Basel)       Date:  2021-02-22       Impact factor: 4.546

9.  Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach.

Authors:  Lewis D Turner; Alexander L Nielsen; Lucy Lin; Sabine Pellett; Takashi Sugane; Margaret E Olson; Eric A Johnson; Kim D Janda
Journal:  RSC Med Chem       Date:  2021-05-19

10.  Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B.

Authors:  J T Guptill; S M Raja; V C Juel; E B Walter; M Cohen-Wolkowiez; H Hill; E Sendra; B Hauser; P Jackson; G K Swamy
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.